CRIS

Permanent URI for this communityhttps://investigadores.udd.cl/handle/123456789/1

Browse

Search Results

Now showing 1 - 10 of 22

Some of the metrics are blocked by your
consent settings
Access to Treatment for Chronic Obstructive Pulmonary Disease in the Americas: A Call for Action. A Joint Perspective from the Brazilian Thoracic Society, Canadian Thoracic Society, Latin American Thoracic Society, and the American Thoracic Society
(2024)
Francesca Polverino
;
Mohit Bhutani
;
Gustavo Zabert
;
Frederico Leon Arrabal Fernandes
;
CZISCHKE LJUBETIC, KAREN NICOLE
Scopus© Citations 2
Some of the metrics are blocked by your
consent settings
Dermatitis por contacto alérgica en el párpado: diagnóstico, diagnóstico diferencial y tratamiento
(2024)
Edinson Lopez
;
Paloma Matus
;
Daniela Calderón
;
Roberto Valdes
1
Some of the metrics are blocked by your
consent settings
Severe pertussis: State of the art
(2012)
Alejandro Donoso
;
Daniela Arriagada Santis
;
Pablo Cruces
;
Franco Díaz
1Scopus© Citations 17
Some of the metrics are blocked by your
consent settings
Clinicians’ preferences and attitudes towards the use of lithium in the maintenance treatment of bipolar disorders around the world: a survey from the ISBD Lithium task force
(2023-12-01)
Hidalgo-Mazzei, Diego
;
Mantingh, Tim
;
Pérez de Mendiola, Xavier
;
Samalin, Ludovic
;
UNDURRAGA FOURCADE, JUAN PABLO
Background: Lithium has long been considered the gold-standard pharmacological treatment for the maintenance treatment of bipolar disorders (BD) which is supported by a wide body of evidence. Prior research has shown a steady decline in lithium prescriptions during the last two decades. We aim to identify potential factors explaining this decline across the world with an anonymous worldwide survey developed by theInternational Society for Bipolar Disorders (ISBD) Task Force “Role of Lithium in Bipolar Disorders” anddistributed by diverse academic and professional international channels. Results: A total of 886 responses were received of which 606 completed the entirequestionnaire while 206 completed it partially. Respondents were from 43 different countries comprising allcontinents. Lithium was the most preferred treatment option for the maintenance of BD patients (59%). The mostrelevant clinical circumstances in which lithium was the preferred option were in patients with BD I (53%), afamily history of response (18%), and a prior response during acute treatment (17%). In contrast, Lithium wasnot the preferred option in case of patients´ negative beliefs and/or attitudes towards lithium (13%), acuteside-effects or tolerability problems (10%) and intoxication risk (8%). Clinicians were less likely to preferlithium as a first option in BD maintenance phase when practising in developing economy countries [X2 (1,N = 430) = 9465, p = 0.002)] and private sectors [X2 (1, N = 434) = 8191, p = 0.004)]. Conclusions: Clinicians’ preferences and attitudes towards the use of lithium in the maintenancetreatment of bipolar disorders appear to be affected by both the patients’ beliefs and the professionalcontexts where clinicians provide their services. More research involving patients is needed for identifyingtheir attitudes toward lithium and factors affecting its use, particularly in developing economies.
Scopus© Citations 28 1
Some of the metrics are blocked by your
consent settings
Recurrence of hepatocellular carcinoma after liver transplantation: Prognostic and predictive factors of survival in a Latin American cohort
(2020)
Claudia Maccali
;
Aline L. Chagas
;
Ilka Boin
;
Emilio Quiñonez
;
Sebastián Marciano
13Scopus© Citations 18
Some of the metrics are blocked by your
consent settings
Updated clinical practice recommendations for managing adults with 22q11.2 deletion syndrome
(2023)
Erik Boot
;
Sólveig Óskarsdóttir
;
Joanne C.Y. Loo
;
Terrence Blaine Crowley
;
Ani Orchanian-Cheff
2Scopus© Citations 78
Some of the metrics are blocked by your
consent settings
Updated clinical practice recommendations for managing children with 22q11.2 deletion syndrome
(2023)
Sólveig Óskarsdóttir
;
Erik Boot
;
Terrence Blaine Crowley
;
Joanne C.Y. Loo
;
Jill M. Arganbright
Scopus© Citations 50 2
Some of the metrics are blocked by your
consent settings
Frequency of NMOSD misdiagnosis in a cohort from Latin America: Impact and evaluation of different contributors
(2022)
Edgar Carnero Contentti
;
Pablo A López
;
Juan Criniti
;
Ricardo Alonso
;
Berenice Silva
<jats:sec><jats:title>Background:</jats:title><jats:p> Neuromyelitis optica spectrum disorder (NMOSD) misdiagnosis (i.e. the incorrect diagnosis of patients who truly have NMOSD) remains an issue in clinical practice. We determined the frequency and factors associated with NMOSD misdiagnosis in patients evaluated in a cohort from Latin America. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> We retrospectively reviewed the medical records of patients with NMOSD, according to the 2015 diagnostic criteria, from referral clinics in six Latin American countries (Argentina, Chile, Paraguay, Colombia, Ecuador, and Venezuela). Diagnoses prior to NMOSD and ultimate diagnoses, demographic, clinical and paraclinical data, and treatment schemes were evaluated. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> A total of 469 patients presented with an established diagnosis of NMOSD (73.2% seropositive) and after evaluation, we determined that 56 (12%) patients had been initially misdiagnosed with a disease other than NMOSD. The most frequent alternative diagnoses were multiple sclerosis (MS; 66.1%), clinically isolated syndrome (17.9%), and cerebrovascular disease (3.6%). NMOSD misdiagnosis was determined by MS/NMOSD specialists in 33.9% of cases. An atypical MS syndrome was found in 86% of misdiagnosed patients, 50% had NMOSD red flags in brain and/or spinal magnetic resonance imaging (MRI), and 71.5% were prescribed disease-modifying drugs. </jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p> NMOSD misdiagnosis is relatively frequent in Latin America (12%). Misapplication and misinterpretation of clinical and neuroradiological findings are relevant factors associated with misdiagnosis. </jats:p></jats:sec>
11Scopus© Citations 14
Some of the metrics are blocked by your
consent settings
Neurogenic Orthostatic Hypotension. Lessons From Synucleinopathies
(2020)
IDIAQUEZ RIOS, JUAN FRANCISCO
;
IDIAQUEZ RIOS, JUAN FRANCISCO
;
Juan Carlos Casar
;
Italo Biaggioni
<jats:title>Abstract</jats:title> <jats:p>Maintenance of upright blood pressure critically depends on the autonomic nervous system and its failure leads to neurogenic orthostatic hypotension (NOH). The most severe cases are seen in neurodegenerative disorders caused by abnormal α-synuclein deposits: multiple system atrophy (MSA), Parkinson’s disease, Lewy body dementia, and pure autonomic failure (PAF). The development of novel treatments for NOH derives from research in these disorders. We provide a brief review of their underlying pathophysiology relevant to understand the rationale behind treatment options for NOH. The goal of treatment is not to normalize blood pressure but rather to improve quality of life and prevent syncope and falls by reducing symptoms of cerebral hypoperfusion. Patients not able to recognize NOH symptoms are at a higher risk for falls. The first step in the management of NOH is to educate patients on how to avoid high-risk situations and providers to identify medications that trigger or worsen NOH. Conservative countermeasures, including diet and compression garments, should always precede pharmacologic therapies. Volume expanders (fludrocortisone and desmopressin) should be used with caution. Drugs that enhance residual sympathetic tone (pyridostigmine and atomoxetine) are more effective in patients with mild disease and in MSA patients with spared postganglionic fibers. Norepinephrine replacement therapy (midodrine and droxidopa) is more effective in patients with neurodegeneration of peripheral noradrenergic fibers like PAF. NOH is often associated with other cardiovascular diseases, most notably supine hypertension, and treatment should be adapted to their presence.</jats:p>
Scopus© Citations 19 1
Some of the metrics are blocked by your
consent settings
First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, <i>Grupo Latino Americano de Estudio del Lupus</i>)–Pan-American League of Associations of Rheumatology (PANLAR)
(2018)
Bernardo A Pons-Estel
;
Eloisa Bonfa
;
Enrique R Soriano
;
Mario H Cardiel
;
Ariel Izcovich
<jats:p>Systemic lupus erythematosus (SLE), a complex and heterogeneous autoimmune disease, represents a significant challenge for both diagnosis and treatment. Patients with SLE in Latin America face special problems that should be considered when therapeutic guidelines are developed. The objective of the study is to develop clinical practice guidelines for Latin American patients with lupus. Two independent teams (rheumatologists with experience in lupus management and methodologists) had an initial meeting in Panama City, Panama, in April 2016. They selected a list of questions for the clinical problems most commonly seen in Latin American patients with SLE. These were addressed with the best available evidence and summarised in a standardised format following the Grading of Recommendations Assessment, Development and Evaluation approach. All preliminary findings were discussed in a second face-to-face meeting in Washington, DC, in November 2016. As a result, nine organ/system sections are presented with the main findings; an ‘overarching’ treatment approach was added. Special emphasis was made on regional implementation issues. Best pharmacologic options were examined for musculoskeletal, mucocutaneous, kidney, cardiac, pulmonary, neuropsychiatric, haematological manifestations and the antiphospholipid syndrome. The roles of main therapeutic options (ie, glucocorticoids, antimalarials, immunosuppressant agents, therapeutic plasma exchange, belimumab, rituximab, abatacept, low-dose aspirin and anticoagulants) were summarised in each section. In all cases, benefits and harms, certainty of the evidence, values and preferences, feasibility, acceptability and equity issues were considered to produce a recommendation with special focus on ethnic and socioeconomic aspects. Guidelines for Latin American patients with lupus have been developed and could be used in similar settings.</jats:p>
Scopus© Citations 88 7

CRIS

Browse

Filters

Settings

Sort By

Results per page

Search Results